Cargando…
Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway
Doxorubicin (DOX), an anthracycline type of chemotherapy, is an effective therapy for several types of cancer, but serious side effects, such as severe hepatotoxicity, limit its use currently. Accordingly, an effective therapeutic strategy to prevent DOX-related hepatotoxicity is urgently needed. Th...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468578/ https://www.ncbi.nlm.nih.gov/pubmed/36110535 http://dx.doi.org/10.3389/fphar.2022.940406 |
_version_ | 1784788444410544128 |
---|---|
author | Xu, Xianchou Liu, Qingbo Li, Jiahao Xiao, Mengjie Gao, Ting Zhang, Xiaohui Lu, Guangping Wang, Jie Guo, Yuanfang Wen, Peinan Gu, Junlian |
author_facet | Xu, Xianchou Liu, Qingbo Li, Jiahao Xiao, Mengjie Gao, Ting Zhang, Xiaohui Lu, Guangping Wang, Jie Guo, Yuanfang Wen, Peinan Gu, Junlian |
author_sort | Xu, Xianchou |
collection | PubMed |
description | Doxorubicin (DOX), an anthracycline type of chemotherapy, is an effective therapy for several types of cancer, but serious side effects, such as severe hepatotoxicity, limit its use currently. Accordingly, an effective therapeutic strategy to prevent DOX-related hepatotoxicity is urgently needed. Through the inhibition of oxidative stress, fibroblast growth factor 1 (FGF1) is an effect therapy for a variety of liver diseases, but its use is limited by an increased risk of tumorigenesis due to hyperproliferation. Resveratrol (RES), a natural product, inhibits the growth of many cancer cell lines, including liver, breast, and prostate cancer cells. Therefore, this study explored whether and how RES in combination with FGF1 can alleviate DOX-induced hepatotoxicity. The results showed that RES or FGF1 alone improved DOX-induced hepatic inflammation, apoptosis and oxidative stress, and these adverse effects were further attenuated after treatment with both RES and FGF1. Mechanistically, both in vivo and in vitro results showed that RES/FGF1 reduced oxidative stress and thereby alleviated liver injury by promoting nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) and subsequently upregulating expression of antioxidant proteins in an adenosine monophosphate-activated protein kinase (AMPK)-dependent manner. Together, our results not only demonstrate that co-treatment with RES and FGF1 significantly inhibited DOX-induced hepatic inflammation and apoptosis, but also that co-treatment with RES and FGF1 markedly suppressed DOX-induced hepatic oxidative stress, via targeting the AMPK/NRF2 pathway and subsequently ameliorating hepatic dysfunction. Thus, the combination of RES and FGF1 may provide a new therapeutic strategy for limiting DOX-induced hepatotoxicity. |
format | Online Article Text |
id | pubmed-9468578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94685782022-09-14 Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway Xu, Xianchou Liu, Qingbo Li, Jiahao Xiao, Mengjie Gao, Ting Zhang, Xiaohui Lu, Guangping Wang, Jie Guo, Yuanfang Wen, Peinan Gu, Junlian Front Pharmacol Pharmacology Doxorubicin (DOX), an anthracycline type of chemotherapy, is an effective therapy for several types of cancer, but serious side effects, such as severe hepatotoxicity, limit its use currently. Accordingly, an effective therapeutic strategy to prevent DOX-related hepatotoxicity is urgently needed. Through the inhibition of oxidative stress, fibroblast growth factor 1 (FGF1) is an effect therapy for a variety of liver diseases, but its use is limited by an increased risk of tumorigenesis due to hyperproliferation. Resveratrol (RES), a natural product, inhibits the growth of many cancer cell lines, including liver, breast, and prostate cancer cells. Therefore, this study explored whether and how RES in combination with FGF1 can alleviate DOX-induced hepatotoxicity. The results showed that RES or FGF1 alone improved DOX-induced hepatic inflammation, apoptosis and oxidative stress, and these adverse effects were further attenuated after treatment with both RES and FGF1. Mechanistically, both in vivo and in vitro results showed that RES/FGF1 reduced oxidative stress and thereby alleviated liver injury by promoting nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) and subsequently upregulating expression of antioxidant proteins in an adenosine monophosphate-activated protein kinase (AMPK)-dependent manner. Together, our results not only demonstrate that co-treatment with RES and FGF1 significantly inhibited DOX-induced hepatic inflammation and apoptosis, but also that co-treatment with RES and FGF1 markedly suppressed DOX-induced hepatic oxidative stress, via targeting the AMPK/NRF2 pathway and subsequently ameliorating hepatic dysfunction. Thus, the combination of RES and FGF1 may provide a new therapeutic strategy for limiting DOX-induced hepatotoxicity. Frontiers Media S.A. 2022-08-30 /pmc/articles/PMC9468578/ /pubmed/36110535 http://dx.doi.org/10.3389/fphar.2022.940406 Text en Copyright © 2022 Xu, Liu, Li, Xiao, Gao, Zhang, Lu, Wang, Guo, Wen and Gu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Xu, Xianchou Liu, Qingbo Li, Jiahao Xiao, Mengjie Gao, Ting Zhang, Xiaohui Lu, Guangping Wang, Jie Guo, Yuanfang Wen, Peinan Gu, Junlian Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway |
title | Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway |
title_full | Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway |
title_fullStr | Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway |
title_full_unstemmed | Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway |
title_short | Co-Treatment With Resveratrol and FGF1 Protects Against Acute Liver Toxicity After Doxorubicin Treatment via the AMPK/NRF2 Pathway |
title_sort | co-treatment with resveratrol and fgf1 protects against acute liver toxicity after doxorubicin treatment via the ampk/nrf2 pathway |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468578/ https://www.ncbi.nlm.nih.gov/pubmed/36110535 http://dx.doi.org/10.3389/fphar.2022.940406 |
work_keys_str_mv | AT xuxianchou cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway AT liuqingbo cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway AT lijiahao cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway AT xiaomengjie cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway AT gaoting cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway AT zhangxiaohui cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway AT luguangping cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway AT wangjie cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway AT guoyuanfang cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway AT wenpeinan cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway AT gujunlian cotreatmentwithresveratrolandfgf1protectsagainstacutelivertoxicityafterdoxorubicintreatmentviatheampknrf2pathway |